Dossier assessment
Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Children between 6 and 11 years of age with severe asthma with type 2 inflammation which is not properly controlled despite moderate-to-high-dose inhaled corticosteroids (ICS) plus one further drug as maintenance treatment.
Added benefit not proven
Project details
- Project no.
- A22-46
- Commission
- Commission awarded on 19.04.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Children's and adolescents' health
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on Jul 15, 2022.
Connected Projects
-
Dossier assessment
Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic spontaneous urticaria in children >= 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic spontaneous urticaria in adults and adolescents 12 years and above) – Benefit assessment according to §35a
Status: Commission completed
-
Dossier assessment
Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed